Marken opens two pharmaceutical depots in New York & Germany

Marken announced today the completion of the first phase of its plan to create a global pharmaceutical depot network that will allow it to satisfy its client's needs for global distribution. Two new depots have been completed:  one in Frankfurt, Germany and one in Farmingdale, New York. The launch of these two central depots, when added to the existing operational depots in Singapore, Mexico and Argentina and further supplemented by its own 3rd party depot network, now completes Phase I of the global Marken depot network plan. This network has been built based on an extensive analysis of client needs as well as geographical needs, allowing large Phase III clinical trials to be conducted in a cost efficient and optimized manner.

"Today marks an important milestone for Marken.  Having these two new central depots allows us to serve our clients with global distribution services and, more importantly, to serve our clients who seek comprehensive and efficient global distribution.  Phase One is complete.  We are now pushing forward with Phase Two, which will include more depots in key countries around the world such as China, Brazil and Russia," said Gerit Offenhauser, Senior Vice President, Clinical Trials Distribution for Marken.

Marken's depots provide secure temperature controlled storage and distribution for drugs, medical devices and diagnostic equipment.  They are located near existing branch operations in order to take advantage of well established customer service, operations import /export and administrative support. Each of Marken's depots are connected through the Solo platform, a state-of-the-art, 21 CFR part 11 validated, cloud based inventory management system which can interface with IRT for improved inventory reconciliation.  This interface allows our client to track dosages at the patient level.

Wes Wheeler, Chief Executive Officer of Marken said "We are proud to expand our pharmaceutical service depot network to Frankfurt and New York. Having a presence in these cities ensures that Marken continues to serve our clients with full service, global clinical supply chain solutions. Marken will continue to invest in facilities and technologies which will provide the highest quality courier and logistics services."

About Marken

Marken is the leading global clinical supply chain solutions provider dedicated to the pharmaceutical and life sciences industries, supporting over 49,000 clinical investigators in more than 150 countries. Marken integrates Depot and Logistics services into solutions that extend the reach of clinical trials to even the most remote treatment in naive geographies.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita.

Decentralized study company Medable has raised a large $91 million funding round as it continues to ramp up the deals in 2020.

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.